# PRIMA-HF: Predicting Myocardial Recovery in Heart Failure Using Cardiac Imaging HAI-HF: High Dosing vs. Standard Dosing Adenosine During Myocardial Perfusion in Heart Failure

Study · id `cardio:ct-nct07243119` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07243119](<https://clinicaltrials.gov/study/NCT07243119>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07243119

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 180 participants.

## Technical summary

Registry record NCT07243119. Randomized; quadruple masking; primary purpose diagnostic. Start 2025-12-08 (actual); primary completion 2029-04-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose diagnostic
- Phase: Phase 4
- Enrolled: 180 participants (planned count; ClinicalTrials.gov record NCT07243119, source copy `cardio:ctgov-nct07243119-2025-12-26`, retrieved 2026-10-26)
- Started: 2025-12-08 (actual) (ClinicalTrials.gov record NCT07243119, source copy `cardio:ctgov-nct07243119-2025-12-26`, retrieved 2026-10-26)
- Primary completion: 2029-04-30 (anticipated) (ClinicalTrials.gov record NCT07243119, source copy `cardio:ctgov-nct07243119-2025-12-26`, retrieved 2026-10-26)
- Completion: 2029-04-30 (anticipated) (ClinicalTrials.gov record NCT07243119, source copy `cardio:ctgov-nct07243119-2025-12-26`, retrieved 2026-10-26)
- Countries: Denmark (ClinicalTrials.gov record NCT07243119, source copy `cardio:ctgov-nct07243119-2025-12-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ENROLLING\_BY\_INVITATION" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07243119-2025-12-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: PRIMA-HF: Predicting Myocardial Recovery in Heart Failure Using Cardiac Imaging HAI-HF: High Dosing vs. Standard Dosing Adenosine During Myocardial Perfusion in Heart Failure
- Acronym: PRIMA-HF
- Condition: Heart Failure and Reduced Ejection Fraction
- Condition: Heart Failure
- Intervention (Diagnostic test): HAI-HF: Adenosine Stress \[¹⁵O\]H₂O PET Imaging
- Intervention (Drug): Two different doses of adenosine
- Lead sponsor: Gødstrup Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart failure with reduced ejection fraction (HFrEF) (`cardio:hfref`)
- Registry lists this organization as the lead sponsor: Gødstrup Hospital (`cardio:org-gdstrup-hospital-114fb1`)

## Provenance

Content hash: 430b0f79cd317614f1a4ba8959d12d7b92d9098aa81d29ca307117893de81bac
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
